D-0511-2017 Class III Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

FDA drug recall D-0511-2017 was initiated by Teva Pharmaceuticals USA on Feb 17, 2017 and is designated Class III. Reason for recall: Failed Dissolution Specifications: low out of specification dissolution results found during stability testing. The recall status is terminated (terminated Feb 5, 2018). Affected quantity: 25,916 cartons.

Recall details

Product Type
Drugs
Report Date
Mar 15, 2017
Initiation Date
Feb 17, 2017
Termination Date
Feb 5, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
25,916 cartons

Product description

Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.

Reason for recall

Failed Dissolution Specifications: low out of specification dissolution results found during stability testing.

Distribution pattern

Nationwide in the United States and Puerto Rico

Code information

Lot # 34025762A, Exp 06/17

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0511-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0511-2017. Report a data issue: hello@regdatalab.com.